Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27.943
Filtrar
1.
Artículo en Chino | MEDLINE | ID: mdl-33794627

RESUMEN

Objective:To analyze the causes and related factors of postoperative complications of Juvenile-onset recurrent respiratory papillomatosis(JORRP). Methods:One hundred and seventy cases of JORRP who underwent surgical treatment in Beijing Tongren Hospital of Capital Medical University from 2017 to 2019 were followed up, and the types of complications, age of first operation, number and frequency of operations, and underwent tracheotomy or not were reviewed. According to the presence or absence of postoperative complications, the patients were divided into a complication group and a control group, and the differences between the two groups and related factors causing postoperative complications were compared. Results:In the 170 cases, 75(44.12%) had postoperative complications, including 52(69.33%) cases of vocal cord adhesion, 37(49.33%) cases of lower airway diffusion, and 25(33.33%) cases of laryngeal stenosis in the complication group. The age of first operation was among 0.3-14 years old, and the total number of surgeries was 14.52(1-54) for each patient during the observation period, with an average annual number of 2.93(0.04-18.39). Compared with the control group, the complication group had 19.07±13.12 total surgeries, the control group had 10.97±9.41 surgeries(P<0.01), annual surgeries ≥4 times(P=0.034), postoperative complications after tracheotomy(P=0.007), and underwent low temperature plasma radiofrequency ablation and photodynamic therapy were more likely to occur than those treated with CO2laser only(P<0.01). Conclusion:The postoperative complications of JORRP include vocal cord adhesion, laryngotracheal stenosis, lower airway dissemination, etc. Multiple and frequent operations, tracheotomy, and different surgical methods are closely related to postoperative complications. The risk of postoperative complications may be increased when children are younger in age of initial operation and with more frequency of surgeries.


Asunto(s)
Infecciones por Papillomavirus , Infecciones del Sistema Respiratorio , Adolescente , Niño , Preescolar , Humanos , Lactante , Complicaciones Posoperatorias/epidemiología , Infecciones del Sistema Respiratorio/epidemiología , Infecciones del Sistema Respiratorio/etiología , Estudios Retrospectivos
2.
Urologiia ; (1): 79-83, 2021 Mar.
Artículo en Ruso | MEDLINE | ID: mdl-33818940

RESUMEN

INTRODUCTION: Infertility is the complex and urgent problem in reproductology. Now HPV involvement in male infertility is considered proven. OBJECTIVES: of the study: To study the etiological structure of human papillomavirus infection (HPV) in ejaculate in men with infertility, as well as to assess the effect of HPV on the parameters of sperm (motility, quantity, morphology). MATERIALS AND METHODS: The analysis of the results of the examination of 71 patients aged 22 to 44 years with a diagnosis of infertility, combined with PVI, with the absence of other risk factors. The assessment of the fertilizing ability of the ejaculate was carried out in accordance with the data and parameters recommended by the WHO (2010) in the clinical diagnostic laboratory. To identify the type of virus used amplification method of DNA - diagnostics (polymerase chain reaction - PCR). The material for the study was ejaculate. RESULTS: The analysis of the ejaculate: asthenozoospermia was detected in 56% cases, asthenoteratozoospermia - 21%, oligoasthenoterozoospermia - 16%, oligoastenozoospermia - 6%. The most frequent HPV types were 16 (60,7%), 18 (54,9%), 33 (49,3%). The most frequent HPV types combinations were 16 with 18 (33,8%), 16 with 33 (35,2%), 18 with 33 (28,2%). The number of virus types has a statistically significant weak correlation with sperm motility (r=-0.267; p=0.0244). Combinations of types 6 and 11, 11 and 16, 16 and 33, 31 and 33 of HPV types more often than others worsened several sperm parameters rather than one. The combination of 6 and 11 HPV types significantly decreases progressive (6.20+/-4.18% and 10.52+/-5.66, p=0.026) and total (11.10+/-5.95% and 17.90+/-6.92%, p=0.0056) motility compared with other combinations of HPV types. The combination of 31 and 33 HPV types was characterized by a large decrease in the total sperm count (12.78 +/- 8.81 million and 21.82+/-9.92 million, p=0.011) and the count of sperm in 1 ml (29.11+/-21.54 million and 53, 35+/-22.13 ppm, p=0.0052) compared with other combinations of HPV types. CONCLUSIONS: According to the results of the study, patients with idiomatic infertility, combined with PVI, have different variants of pathozoospermia.


Asunto(s)
Infertilidad Masculina , Infecciones por Papillomavirus , Adulto , Humanos , Infertilidad Masculina/etiología , Masculino , Papillomaviridae/genética , Infecciones por Papillomavirus/complicaciones , Motilidad Espermática , Espermatozoides , Adulto Joven
4.
Georgian Med News ; (311): 147-151, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33814409

RESUMEN

Apoptosis plays one of the major roles in the progression of human cancers including cervical carcinoma. The aim of our study was to analyse the expression of Cas3, Bax and their correlation with the proliferation index and ER expression status during the progression of cervical intraepithelial neoplasia (CIN). Study included altogether 140 specimens, divided into two major groups, such as: cervical lesions without co-infections and with co-infections. Standard immunohistochemistry was used to detect antigens: Ki67, Cas3, Bax and ER. The study results showed that the expression of Cas3 is significantly decreased whilst the expression of Bax is significantly increased during the progression of CIN in both groups with and without co-infections. The expression of Bax negatively correlates with the expression of Cas3 (r=-42.4, p<0.05) and ER (r=-33.4, p<0.05) and positively correlates with the expression of proliferation marker Ki67 (r=56.3, p<0.05). The results indicate that the deregulated apoptosis measured as increased expression of Bax and Cas3 loss, as well as the increase in proliferation index measured as Ki67 expression is significantly related to the progression of CIN into cervical carcinoma. Therefore, the measuring of mentioned protein expression could be used as the markers of the CIN progression.


Asunto(s)
Proteínas Asociadas a CRISPR , Neoplasia Intraepitelial Cervical , Infecciones por Papillomavirus , Neoplasias del Cuello Uterino , Biomarcadores de Tumor/genética , Neoplasia Intraepitelial Cervical/genética , Femenino , Humanos , Inmunohistoquímica , Neoplasias del Cuello Uterino/genética , Proteína X Asociada a bcl-2/genética
5.
Recurso de Internet en Portugués | LIS - Localizador de Información en Salud | ID: lis-48087

RESUMEN

O câncer do colo do útero está associado à infecção persistente por subtipos oncogênicos do vírus HPV (Papilomavírus Humano), especialmente o HPV-16 e o HPV-18, responsáveis por cerca de 70% dos cânceres cervicais.


Asunto(s)
Infecciones por Papillomavirus , Neoplasias
6.
Anticancer Res ; 41(3): 1157-1161, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33788706

RESUMEN

BACKGROUND/AIM: While in many Western countries the number of tonsillectomies decreases significantly, there is an increasing incidence of oropharyngeal carcinomas. For, obviously, removal of the tonsils will reduce individual risk for tonsil cancer, the question of tonsillectomy as a prevention strategy is suggested. This study focused on this question by carrying out a literature research. MATERIALS AND METHODS: A literature research was performed (www.pubmed.gov; Search words: tonsillectomy, oropharyngeal cancer, tonsil cancer, prevention) without applying additional filters. RESULTS: Out of the 16 identified studies, three population-based studies were evaluated. Individual incidence of tonsil cancer is significantly lower after removal of tonsils; however, risk elimination by tonsillectomy has not been proven. One of the studies revealed increasing numbers of base of the tongue cancer after previous tonsillectomy. CONCLUSION: The increase in oropharynx carcinomas can currently be attributed not to the decreasing tonsillectomy rates, but to the increase in HPV infections. A previous tonsillectomy reduces the individual risk of developing tonsil carcer. Tonsillectomy as prevention for oropharyngeal cancer cannot be recommended and may even be a disadvantage concerning base of the tongue cancers.


Asunto(s)
Neoplasias Orofaríngeas/prevención & control , Tonsilectomía , Humanos , Incidencia , Neoplasias Orofaríngeas/epidemiología , Neoplasias Orofaríngeas/etiología , Infecciones por Papillomavirus/complicaciones , Infecciones por Papillomavirus/epidemiología , Neoplasias Tonsilares/epidemiología , Neoplasias Tonsilares/prevención & control
7.
MMWR Morb Mortal Wkly Rep ; 70(12): 415-420, 2021 Mar 26.
Artículo en Inglés | MEDLINE | ID: mdl-33764964

RESUMEN

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States (1). Although most infections resolve without clinical sequalae, persistent HPV infection can cause cervical, other anogenital, and oropharyngeal cancers and anogenital warts. HPV vaccination has been recommended in the United States at age 11-12 years since 2006 for females and since 2011 for males. Catch-up vaccination is recommended through age 26 years.* A quadrivalent vaccine (4vHPV) targeting types 6, 11, 16, and 18 was mainly used until 2015, when a 9-valent vaccine (9vHPV), targeting the same four types as 4vHPV and five additional types (31, 33, 45, 52, and 58), was introduced; 9vHPV has been the only vaccine available in the United States since the end of 2016 (2). HPV vaccination coverage has increased but remains lower than that of other vaccinations recommended for adolescents (3). A decrease in prevalence of 4vHPV types detected in cervicovaginal swabs among young females from the prevaccine era (2003-2006) to 2007-2010 in the National Health and Nutrition Examination Survey (NHANES) was an early indicator of vaccine impact (2) and was also observed in later periods (4,5). NHANES data from 2017-2018 were included in this analysis to update HPV prevalence estimates among females aged 14-34 years. From the prevaccine era to 2015-2018, significant decreases in 4vHPV-type prevalence occurred among females aged 14-19 years (88%) and 20-24 years (81%). In sexually experienced females, 4vHPV-type prevalence decreased in those who reported receiving ≥1 HPV vaccine dose (97% among those aged 14-19 years, 86% among those aged 20-24 years) and in those who reported no vaccination (87% among those aged 14-19 years, 65% among those aged 20-24 years). Significant declines among unvaccinated females suggest herd effects. These data show increasing impact of HPV vaccination in the United States. HPV vaccination is a critical prevention tool against HPV infection, anogenital warts, and HPV-attributable precancers and cancers. HPV vaccination is highly effective and is recommended routinely at age 11-12 years and through 26 years for persons not already vaccinated.


Asunto(s)
Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/epidemiología , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/administración & dosificación , Adolescente , Adulto , Femenino , Genotipo , Humanos , Papillomaviridae/genética , Prevalencia , Estados Unidos/epidemiología , Adulto Joven
9.
Artículo en Inglés | MEDLINE | ID: mdl-33765753

RESUMEN

INTRODUCTION: The World Health Organization elimination goal for cervical cancer relies on screening 70% of women at ages 35 and 45, preferentially through molecular HPV testing. The SARS-CoV-2 pandemic has led to an unprecedented demand for molecular tests and platforms. Our objective was to gain insight into the impact of SARS-CoV-2 on the actual or anticipated shortage of tests, equipment, consumables, and staff required to deliver molecular HPV laboratory services and to consider the implications for the sustainability and development of cervical screening programs. METHODS: A 19-item online questionnaire was created and made available online between December 2020 and February 2021. Five companies with clinically validated HPV and SARS-CoV-2 tests in their portfolios were invited to provide a statement on the volumes of molecular COVID-19 tests produced, relevant changes to manufacturing capacity, and their current and post-pandemic strategy for HPV tests. RESULTS: We received responses from 57 laboratories representing 30 countries and six continents. Among these, 74% reported experiencing a supply shortage, 54% reported a shortage of personnel, and 33% reported delays in ordering equipment. Three companies described expansion of manufacturing lines, investment in diagnostic infrastructure, and scale-up of manufacturing capacity. Two companies specifically referred to opportunities for the use of platforms for COVID-19 testing to support HPV testing in time. CONCLUSIONS: The demand for SARS-CoV-2 testing is competing with HPV testing, compounded by a shortage of staff. This represents a challenge for existing laboratory services and for settings keen to implement HPV-based screening. However, supply challenges may be addressed in time, given the significant investment in manufacturing capacity. In addition, innovation around molecular COVID-19 testing systems may result in solutions that address the shortage of rapid low-cost HPV testing systems for low-resource settings. Finally, because the demand for COVID-19 testing is likely to decrease, this may release both workforce and platform capacity for high-throughput HPV testing. The global health community should be alert to the opportunities around innovation and capacity if cervical cancer elimination goals are to be reached.


Asunto(s)
/epidemiología , Tamizaje Masivo/estadística & datos numéricos , Infecciones por Papillomavirus/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico , Adulto , Detección Precoz del Cáncer/estadística & datos numéricos , Femenino , Humanos , Persona de Mediana Edad , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/prevención & control , Neoplasias del Cuello Uterino/prevención & control , Adulto Joven
11.
Am Fam Physician ; 103(7): 407-416, 2021 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-33788514

RESUMEN

The HIV epidemic is an important public health priority. Transmissions continue to occur despite effective therapies that make HIV preventable and treatable. Approximately one-half of people with HIV are not receiving suppressive antiretroviral therapy (ART). Starting ART early, followed by continuous lifetime treatment, most effectively achieves durable virologic suppression and restoration of immune function that can improve clinical outcomes and prevent transmission to partners who are seronegative. National treatment guidelines include ART options that can be offered immediately after diagnosis, even before the results of baseline HIV drug-resistance testing are available. Initial ART selection should be guided by co-occurring conditions, including viral hepatitis, medications, and other factors such as pregnancy. Identifying and addressing psychosocial barriers to care is a key element of ensuring long-term adherence to treatment. The initial physical examination typically reveals no clinical manifestations of HIV in the absence of advanced disease. A comprehensive laboratory evaluation, including HIV viral load and CD4 lymphocyte monitoring, is necessary to guide decision-making for treatment, opportunistic infection prophylaxis, and vaccinations. The initial management of people with HIV presents a unique opportunity for family physicians to improve patients' long-term health care and reduce HIV transmissions.


Asunto(s)
Antirretrovirales/uso terapéutico , Terapia Antirretroviral Altamente Activa/métodos , Infecciones por VIH/terapia , Guías de Práctica Clínica como Asunto , Infecciones Oportunistas Relacionadas con el SIDA/prevención & control , Neoplasias del Ano/diagnóstico , Recuento de Linfocito CD4 , Manejo de la Enfermedad , Detección Precoz del Cáncer , Femenino , Infecciones por VIH/diagnóstico , Infecciones por VIH/transmisión , Vacunas contra la Hepatitis A/uso terapéutico , Vacunas contra Hepatitis B/uso terapéutico , Hepatitis Viral Humana/diagnóstico , Hepatitis Viral Humana/prevención & control , Herpes Zóster/prevención & control , Vacuna contra el Herpes Zóster/uso terapéutico , Humanos , Vacunas contra la Influenza/uso terapéutico , Gripe Humana/prevención & control , Masculino , Tamizaje Masivo , Cumplimiento de la Medicación , Infecciones por Papillomavirus/diagnóstico , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/uso terapéutico , Infecciones por Pneumocystis/prevención & control , Enfermedades de Transmisión Sexual/diagnóstico , Tuberculosis/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico , Carga Viral
12.
Sci Rep ; 11(1): 4954, 2021 03 02.
Artículo en Inglés | MEDLINE | ID: mdl-33654181

RESUMEN

The prophylactic vaccines available to protect against infections by HPV are well tolerated and highly immunogenic. People with HIV have a higher risk of developing HPV infection and HPV-associated cancers due to a lower immune response, and due to viral interactions. We performed a systematic review of RCTs to assess HPV vaccines efficacy and safety on HIV-infected people compared to placebo or no intervention in terms of seroconversion, infections, neoplasms, adverse events, CD4+ T-cell count and HIV viral load. The vaccine-group showed a seroconversion rate close to 100% for each vaccine and a significantly higher level of antibodies against HPV vaccine types, as compared to the placebo group (MD = 4333.3, 95% CI 2701.4; 5965.1 GMT EL.U./ml for HPV type 16 and MD = 1408.8, 95% CI 414.8; 2394.7 GMT EL.U./ml for HPV type 18). There were also no differences in terms of severe adverse events (RR = 0.6, 95% CI 0.2; 1.6) and no severe adverse events (RR = 0.6, 95% CI 0.9; 1.2) between vaccine and placebo groups. Secondary outcomes, such as CD4 + T-cell count and HIV viral load, did not differ between groups (MD = 14.8, 95% CI - 35.1; 64.6 cells/µl and MD = 0.0, 95% CI - 0.3; 0.3 log10 RNA copies/ml, respectively). Information on the remaining outcomes was scarce and that did not allow us to combine the data. The results support the use of the HPV vaccine in HIV-infected patients and highlight the need of further RCTs assessing the effectiveness of the HPV vaccine on infections and neoplasms.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Infecciones por VIH/inmunología , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/inmunología , Seguridad del Paciente , Adolescente , Adulto , Anticuerpos Antivirales , Recuento de Linfocito CD4 , Linfocitos T CD4-Positivos/virología , Femenino , Humanos , Masculino , Infecciones por Papillomavirus/virología , Vacunas contra Papillomavirus/efectos adversos , Salud Pública , Ensayos Clínicos Controlados Aleatorios como Asunto , Riesgo , Resultado del Tratamiento , Carga Viral , Esparcimiento de Virus , Adulto Joven
13.
Talanta ; 227: 122154, 2021 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-33714462

RESUMEN

Infectious diseases caused by viruses such as SARS-CoV-2 and HPV have greatly endangered human health. The nucleic acid detection is essential for the early diagnosis of diseases. Here, we propose a method called PLCR (PfAgo coupled with modified Ligase Chain Reaction for nucleic acid detection) which utilizes PfAgo to only use DNA guides longer than 14-mer to specifically cleave DNA and LCR to precisely distinguish single-base mismatch. PLCR can detect DNA or RNA without PCR at attomolar sensitivities, distinguish single base mutation between the genome of wild type SARS-CoV-2 and its mutant spike D614G, effectively distinguish the novel coronavirus from other coronaviruses and finally achieve multiplexed detection in 70 min. Additionally, LCR products can be directly used as DNA guides without additional input guides to simplify primer design. With desirable sensitivity, specificity and simplicity, the method can be extended for detecting other pathogenic microorganisms.


Asunto(s)
Proteínas Argonauta/química , ADN Viral/análisis , Reacción en Cadena de la Ligasa/métodos , Pyrococcus furiosus/enzimología , ARN Viral/análisis , Alphapapillomavirus/química , Alphapapillomavirus/aislamiento & purificación , ADN Viral/química , Humanos , Límite de Detección , Mutación , Infecciones por Papillomavirus/diagnóstico , ARN Viral/química , /aislamiento & purificación , Sensibilidad y Especificidad , Glicoproteína de la Espiga del Coronavirus/genética
14.
Prev Med ; 144: 106294, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33678225

RESUMEN

Cervical cancer remains the fourth most common cancer in women, with 85% of deaths occurring in LMICs. Despite the existence of effective vaccine and screening tools, efforts to reduce the burden of cervical cancer must be considered in the context of the social structures within the health systems of LMICs. Compounding this existing challenge is the global COVID-19 pandemic, declared in March 2020. While it is too soon to tell how health systems priorities will change as a result of COVID-19 and its impact on the cervical cancer elimination agenda, there are opportunities to strengthen cervical screening by leveraging on several trends. Many LMICs maximized the strengths of their long established community-based primary care and public health systems with expansion of surveillance systems which incorporated mobile technologies. LMICs can harness the momentum of the measures taken against COVID-19 to consolidate the efforts against cervical cancer. Self-sampling, molecular human papillomavirus (HPV) testing and digital health will shift health systems towards stronger public health and primary care networks and away from expensive hospital-based care investments. While COVID-19 will change health systems priorities in LMICs in ways that may de-prioritize cervical cancer screening, there are significant opportunities for integration into longer-term trends towards universal health coverage, self-care and digital health.


Asunto(s)
/epidemiología , Países en Desarrollo , Prioridades en Salud , Infecciones por Papillomavirus/diagnóstico , Neoplasias del Cuello Uterino/diagnóstico , /prevención & control , Detección Precoz del Cáncer , Femenino , Humanos
15.
Zhonghua Yu Fang Yi Xue Za Zhi ; 55(3): 428-434, 2021 Mar 06.
Artículo en Chino | MEDLINE | ID: mdl-33730840

RESUMEN

Human papillomavirus infection is the main pathogenic factor leading to cervical cancer. About 630 000 new cancers are caused by HPV infection every year, among which cervical cancer accounts for the highest proportion (83%). The burden of cervical cancer is serious in China. Research data shows that there were nearly 110 000 new cases and nearly 50 000 deaths of cervical cancer in China in 2018, accounting for about 20 percent and 16 percent of the global total of cases and deaths, respectively. The World Health Organization's position paper clearly states that HPV vaccination can effectively prevent the occurrence of HPV-related diseases. Across clinical studies and real world data from around the world, HPV vaccines have shown good efficacy and safety. As of October 2019, 98 countries and regions around the world have included HPV vaccine in their national immunization program. However, with the increase of vaccination coverage and indications, the safety of HPV vaccine has become a global public health issue of high concern. Since the launch of HPV vaccine in 2006, many authorities around the world and countries have conducted long-term monitoring of the safety of HPV vaccine after its launch, and accumulated a large number of safety data, which showed that the HPV vaccine was safe and supported the use of HPV vaccine. In this paper, the safety data related to HPV vaccine in the world and mainland China will be combed to provide reference for the HPV vaccination in China.


Asunto(s)
Infecciones por Papillomavirus , Vacunas contra Papillomavirus , Neoplasias del Cuello Uterino , China , Femenino , Humanos , Programas de Inmunización , Infecciones por Papillomavirus/prevención & control , Neoplasias del Cuello Uterino/prevención & control , Vacunación
16.
Pan Afr Med J ; 38: 40, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33777308

RESUMEN

Introduction: head and neck cancers have essentially been a disease of the elderly but recent studies are beginning to demonstrate their increasing incidence in young people with infections such as human papilloma virus (HPV). This study was carried out to determine the prevalence of high risk Human papilloma virus (hrHPV) related oropharyngeal carcinoma and its prevalent genotypes as well as their strength of association with HIV in adult Nigerian subjects. Methods: this was a cross-sectional study of 41 patients with oropharyngeal carcinomas seen over a 2-year period. Patients had incisional and/or excisional biopsy done under anesthesia. A portion of the specimen from which the DNA was extracted was placed in Digene HC2 DNA collection device while the 2nd portion for histopathological analysis was fixed using 10% Neutral Buffered Formalin (NBF) and embedded in paraffin blocks. Oropharyngeal cancer HPV genotyping was done using HPV genotypes 14 real-tm quant kit (SACACE, Italy). The data was analyzed using SPSS version 23. Results: prevalence of HPV was 17.1% with a male to female ratio of 2.7: 1. The identified genotypes were 16, 33, 35 and 52 with 28.6% of patients having more than one genotype. Most of the age groups studied were affected. Squamous cell carcinoma and ameloblastic carcinoma were the cancers associated with HPV. HPV was not identified in the HIV positive patients. Conclusion: high-risk human papilloma virus genotypes 16, 33, 35 and 52 are associated with oropharyngeal carcinoma in Nigeria but were not found in HIV patients. This finding provides a strong evidence for the use of the 9-valent prophylactic vaccine for the prevention of oropharyngeal cancer in Nigeria. Public awareness and HPV prevention strategies should reduce significantly the incidence of oropharyngeal carcinomas in our environment.


Asunto(s)
Neoplasias Orofaríngeas/virología , Papillomaviridae/genética , Infecciones por Papillomavirus/complicaciones , Adulto , Anciano , Ameloblastoma/epidemiología , Ameloblastoma/virología , Carcinoma de Células Escamosas/epidemiología , Carcinoma de Células Escamosas/virología , Estudios Transversales , ADN Viral/genética , Femenino , Genotipo , Infecciones por VIH/epidemiología , Neoplasias de Cabeza y Cuello/epidemiología , Neoplasias de Cabeza y Cuello/patología , Neoplasias de Cabeza y Cuello/virología , Humanos , Masculino , Persona de Mediana Edad , Nigeria , Neoplasias Orofaríngeas/epidemiología , Neoplasias Orofaríngeas/patología , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/epidemiología , Infecciones por Papillomavirus/virología , Prevalencia , Adulto Joven
17.
Gen Dent ; 69(2): 23-27, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33661110

RESUMEN

Human papillomavirus (HPV) has a nearly ubiquitous prevalence within the adolescent and adult populations worldwide. The virus has been implicated for decades in cervical and uterine cancers, but recent data have shown an increase in cases of virally related oropharyngeal squamous cell carcinoma in both male and female cohorts. The objective of this article is to review the oral health implications of HPV infection, including oral and oropharyngeal prevalence, manifestations, neoplastic potential of HPV-associated head and neck lesions, treatment modalities, and vaccine use. The article will also discuss the continuing education needs of oral healthcare providers. Dental professionals should routinely screen patients for oral and oropharyngeal manifestations of HPV infection, seek timely referral for therapeutic intervention of potentially malignant lesions, and become strong proponents of HPV vaccinations for at-risk patients.


Asunto(s)
Alphapapillomavirus , Carcinoma de Células Escamosas , Neoplasias Orofaríngeas , Infecciones por Papillomavirus , Adolescente , Adulto , Odontólogos , Femenino , Humanos , Masculino , Neoplasias Orofaríngeas/diagnóstico , Neoplasias Orofaríngeas/epidemiología , Neoplasias Orofaríngeas/terapia , Papillomaviridae , Infecciones por Papillomavirus/complicaciones , Infecciones por Papillomavirus/diagnóstico
18.
J Craniomaxillofac Surg ; 49(4): 312-316, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33612410

RESUMEN

Although mostly associated with good survival outcomes, some patients with HPV-positive oropharyngeal squamous cell carcinoma develop distant metastasis and face dire prognosis. The aim of this study was to analyze distant metastatic patients in regards to survival, clinical staging, therapy approach and p16/HPV status. This retrospective single-centre study assessed patients with HPV-associated oropharyngeal cancer with distant metastasis treated in a tertiary referral center from 2005 to 2019. Overall- (OS) and survival after diagnosis of distant metastasis (OMS), clinical staging and different therapy approaches were assessed. Moreover, the overall mortality was assessed, as well as the association of different therapy approaches and p16/HPV status with the survival outcome. Out of 211 patients with HPV-associated oropharyngeal cancer that were treated in the study period, 15 developed distant metastases (7.1%). Median OS and OMS of the total group were 11 months (range 0.1-32 months) and 3 months (range 0.1-21 months), respectively. The overall mortality rate was 53.3% (n = 8). Significantly better outcome was present in patients treated with primary chemoradiotherapy (median OS 17 months vs. not reached, p = .03, median OMS 8 months vs not reached, p = .05). The OMS was significantly better in patients treated with chemotherapy initially after diagnosis (mean OMS 21 months vs 4 months; P = .001). Surgical resection after initial diagnosis was associated with a significantly shorter OMS (median OMS 3 vs. 21 months, p = .005). Interestingly, postoperative adjuvant therapy was delayed in all of these cases due to surgical site complications. Systemic treatment after initial diagnosis may be beneficial in clinical outcome of HPV associated distant metastases. Furthermore, surgical site complications should be treated with immediate care in order to avoid delay of adjuvant therapy. Further studies are warranted for validation of our results.


Asunto(s)
Carcinoma de Células Escamosas , Neoplasias de Cabeza y Cuello , Neoplasias Orofaríngeas , Infecciones por Papillomavirus , Carcinoma de Células Escamosas/terapia , Humanos , Neoplasias Orofaríngeas/terapia , Papillomaviridae , Pronóstico , Estudios Retrospectivos , Carcinoma de Células Escamosas de Cabeza y Cuello
19.
An Bras Dermatol ; 96(2): 125-138, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33637397

RESUMEN

In this nonsystematic review, the complementary diagnosis, treatment, prevention, and control of human papillomavirus are discussed. The histopathology is addressed regarding its indications, main findings and limitations, as a complementary diagnostic method largely used by dermatologists. Electron microscopy is briefly reviewed, along with its contribution to the accumulated knowledge on HPV, as well as the relevance of research in using this technology for future advances in diagnosis and treatment. Molecular information about the virus is continuously increasing, and the practical applications of HPV serology, molecular identification and genotyping are discussed. Vaccines are a valuable tool in primary HPV infection prevention and are now available in many countries; their composition, indications, and adverse effects are revisited. Local and systemic treatment options are reviewed and off-label prescriptions are discussed. Finally, health education focusing on HPV infection as a sexually transmitted infection of worldwide relevance and the many barriers to improve primary and secondary prevention are addressed.


Asunto(s)
Alphapapillomavirus , Infecciones por Papillomavirus , Vacunas contra Papillomavirus , Humanos , Papillomaviridae , Infecciones por Papillomavirus/diagnóstico , Infecciones por Papillomavirus/prevención & control , Factores de Riesgo
20.
Cancer Epidemiol Biomarkers Prev ; 30(2): 245-247, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-33547144

RESUMEN

Self-sampling is poised to be a disruptor for cervical screening. So far, cancer screening has been a causality of COVID-19; however, the opposite may transpire for self-sampling. Self-sampling enables socially distanced cervical screening with an outreach that extends to underserved populations. As evidence mounts that self-sampling is noninferior to clinician-taken samples, the focus for self-sampling is now as a primary screening option for all women. Now, we have evidence from a modeling study (using Australia as an exemplar) to suggest that program effectiveness with primary self-sampling would be better than the current program, even if sensitivity is lower. Regulatory issues, suitable triage strategies, and clear communication about self-sampling are hurdles yet to be overcome. Nevertheless, existing evidence coupled with COVID-19 could be the tipping point for wider introduction of self-sampling.See related article by Smith et al., p. 268.


Asunto(s)
Papillomaviridae , Infecciones por Papillomavirus , Neoplasias del Cuello Uterino , Australia , Detección Precoz del Cáncer , Femenino , Humanos , Tamizaje Masivo , Infecciones por Papillomavirus/diagnóstico , Manejo de Especímenes , Neoplasias del Cuello Uterino/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...